{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:34Z","timestamp":1791232414546,"version":"4.1.0"},"reference-count":214,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Cardiovascular events, including ischemic heart disease, heart failure, and arrhythmia, are common complications after kidney transplantation and continue to be leading causes of graft loss. Kidney transplant recipients have both traditional and transplant-specific risk factors for cardiovascular disease. In the general population, modification of cardiovascular risk factors is the best strategy to reduce cardiovascular events; however, studies evaluating the impact of risk modification strategies on cardiovascular outcomes among kidney transplant recipients are limited. Furthermore, there is only minimal guidance on appropriate cardiovascular screening and monitoring in this unique patient population. This review focuses on the limited scientific evidence that addresses cardiovascular events in kidney transplant recipients. Additionally, we focus on clinical management of specific cardiovascular entities that are more prevalent among kidney transplant recipients (ie, pulmonary hypertension, valvular diseases, diastolic dysfunction) and the use of newer evolving drug classes for treatment of heart failure within this cohort of patients. We note that there are no consensus documents describing optimal diagnostic, monitoring, or management strategies to reduce cardiovascular events after kidney transplantation; however, we outline quality initiatives and research recommendations for the assessment and management of cardiovascular-specific risk factors that could improve outcomes.<\/jats:p>","DOI":"10.1097\/tp.0000000000003990","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T23:01:44Z","timestamp":1638486104000},"page":"1143-1158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["New Approaches to Cardiovascular Disease and Its Management in Kidney Transplant Recipients"],"prefix":"10.1097","volume":"106","author":[{"given":"Fahad","family":"Aziz","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetika","family":"Garg","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Parajuli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Raza","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mandelbrot","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Djamali","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."},{"name":"Division of Transplantation, Department of Surgery, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Dhingra","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, University of Wisconsin\u2013Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association.","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015.","volume":"70","author":"Roth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/ndt\/12.8.1672","article-title":"Patient survival after renal transplantation; more than 25 years follow-up.","volume":"12","author":"Arend","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-1755.2000.00816.x","article-title":"Long-term survival in renal transplant recipients with graft function.","volume":"57","author":"Ojo","year":"2000","journal-title":"Kidney Int"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfy168","article-title":"Causes of renal allograft failure in the UK: trends in UK Renal Registry and National Health Service Blood and Transplant data from 2000 to 2013.","volume":"34","author":"Burton","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R9-20250604","first-page":"154","article-title":"The European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2014: a summary.","volume":"10","author":"Pippias","year":"2017","journal-title":"Clin Kidney J"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000495081","article-title":"Trends in the causes of death among kidney transplant recipients in the United States (1996\u20132014).","volume":"48","author":"Awan","year":"2018","journal-title":"Am J Nephrol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.V1341084","article-title":"Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease.","volume":"13","author":"Rigatto","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1681\/ASN.2004070580","article-title":"Incidence and predictors of myocardial infarction after kidney transplantation.","volume":"16","author":"Lentine","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.","volume":"167","author":"Dhingra","year":"2007","journal-title":"Arch Intern Med"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","article-title":"Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.","volume":"23","author":"Sitara","year":"2004","journal-title":"Matrix Biol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing.","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/fca.11.24","article-title":"Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.","volume":"7","author":"Napoli","year":"2011","journal-title":"Future Cardiol"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2215\/CJN.05081107","article-title":"Management of cardiovascular disease in renal transplant recipients.","volume":"3","author":"Shirali","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.trre.2018.06.002","article-title":"Hypertension guidelines: how do they apply to kidney transplant recipients.","volume":"32","author":"Aziz","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"e13452","DOI":"10.1111\/ctr.13452","article-title":"Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation.","volume":"33","author":"Aziz","year":"2019","journal-title":"Clin Transplant"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mcna.2011.11.003","article-title":"Age as a risk factor.","volume":"96","author":"Dhingra","year":"2012","journal-title":"Med Clin North Am"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.291.18.2204","article-title":"Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring.","volume":"291","author":"Lloyd-Jones","year":"2004","journal-title":"JAMA"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1681\/ASN.2014080834","article-title":"Assessment and management of hypertension in transplant patients.","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/2141-9248.149793","article-title":"Modifiable risk factors of hypertension and socio-demographic profile in Oghara, Delta state; prevalence and correlates.","volume":"5","author":"Ibekwe","year":"2015","journal-title":"Ann Med Health Sci Res"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000450796","article-title":"The triad of sleep apnea, hypertension, and chronic kidney disease: a spectrum of common pathology.","volume":"7","author":"Aziz","year":"2016","journal-title":"Cardiorenal Med"},{"issue":"suppl 3","key":"R27-20250604","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.","volume":"62","author":"Taler","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1592\/phco.23.6.788.32180","article-title":"Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction.","volume":"23","author":"Baroletti","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension.","volume":"25","author":"Hoorn","year":"2012","journal-title":"J Nephrol"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1161\/JAHA.112.000091","article-title":"Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients.","volume":"2","author":"Aftab","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation.","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","article-title":"Thrombotic microangiopathy and associated renal disorders.","volume":"27","author":"Barbour","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1667\/RR2400.1","article-title":"Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation.","volume":"175","author":"Moulder","year":"2011","journal-title":"Radiat Res"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/ajt.12397","article-title":"Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.","volume":"13","author":"Giral","year":"2013","journal-title":"Am J Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/TP.0b013e318234b337","article-title":"Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II.","volume":"92","author":"Kelsch","year":"2011","journal-title":"Transplantation"},{"issue":"suppl 1","key":"R38-20250604","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/nep.12421","article-title":"Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation.","volume":"20","author":"Jobert","year":"2015","journal-title":"Nephrology (Carlton)"},{"issue":"suppl 7","key":"R39-20250604","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.V1191735","article-title":"Explained and unexplained ischemic heart disease risk after renal transplantation.","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1681\/ASN.V71158","article-title":"Cardiovascular disease after renal transplantation.","volume":"7","author":"Kasiske","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2165\/00003495-200464180-00004","article-title":"Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.","volume":"64","author":"Boots","year":"2004","journal-title":"Drugs"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0026-0495(98)90239-6","article-title":"Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways.","volume":"47","author":"Kraemer","year":"1998","journal-title":"Metabolism"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/TP.0b013e318177281e","article-title":"Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.","volume":"86","author":"Celik","year":"2008","journal-title":"Transplantation"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199805150-00023","article-title":"Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin).","volume":"65","author":"Brattstr\u00f6m","year":"1998","journal-title":"Transplantation"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0897190017692920","article-title":"Severe hypertriglyceridemia induced by sirolimus treated with medical management without plasmapheresis: a case report.","volume":"31","author":"Kido","year":"2018","journal-title":"J Pharm Pract"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1365-2036.2004.01923.x","article-title":"Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent.","volume":"19","author":"Firpi","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/TP.0b013e3181caa5e4","article-title":"Sirolimus-induced severe hypertriglyceridemia in a lung transplant recipient.","volume":"89","author":"Fernandez-Bussy","year":"2010","journal-title":"Transplantation"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/kisup.2013.35","article-title":"Chapter 3: assessment of lipid status in children with CKD.","volume":"3","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1681\/ASN.2008010101","article-title":"Statin use is associated with prolonged survival of renal transplant recipients.","volume":"19","author":"Wiesbauer","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R57-20250604","first-page":"CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients.","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association.","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: current status, controversies, and future directions.","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ckj\/sfx149","article-title":"The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary.","volume":"11","author":"Kramer","year":"2018","journal-title":"Clin Kidney J"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5414\/CN110254","article-title":"Non-obstructive coronary angiogram findings prior to kidney transplantation do not predict post-transplant cardiac events.","volume":"94","author":"Aziz","year":"2020","journal-title":"Clin Nephrol"},{"issue":"suppl 10","key":"R64-20250604","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/DMSO.S19027","article-title":"New onset diabetes after transplantation (NODAT): an overview.","volume":"4","author":"Pham","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/TP.0b013e3182584831","article-title":"Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation.","volume":"94","author":"Wauters","year":"2012","journal-title":"Transplantation"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/j.1523-1755.2005.00349.x","article-title":"New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.","volume":"67","author":"Cosio","year":"2005","journal-title":"Kidney Int"},{"key":"R68-20250604","first-page":"175","article-title":"Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients.","volume":"3","author":"Vivek","year":"2010","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc11-1230","article-title":"New-onset diabetes after renal transplantation: risk assessment and management.","volume":"35","author":"Ghisdal","year":"2012","journal-title":"Diabetes Care"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/tri.12042","article-title":"Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation.","volume":"26","author":"Shabir","year":"2013","journal-title":"Transpl Int"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"e006362","DOI":"10.1161\/CIRCHEARTFAILURE.119.006362","article-title":"Validation of cardiovascular magnetic resonance-derived equation for predicted left ventricular mass using the UK Biobank imaging cohort: tool for donor-recipient size matching.","volume":"12","author":"Fung","year":"2019","journal-title":"Circ Heart Fail"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/15733998113096660085","article-title":"Type 2 diabetes mellitus and Invokana: an FDA approved drug.","volume":"9","author":"Akhtar","year":"2013","journal-title":"Curr Diabetes Rev"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"R76-20250604","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"R78-20250604","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"R80-20250604","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"R81-20250604","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus.","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"R82-20250604","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients.","volume":"52","author":"AlKindi","year":"2020","journal-title":"Transplant Proc"},{"key":"R83-20250604","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial.","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"R84-20250604","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ehf2.12850","article-title":"Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring.","volume":"7","author":"Mullens","year":"2020","journal-title":"ESC Heart Fail"},{"key":"R85-20250604","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"key":"R86-20250604","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"R87-20250604","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients.","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"key":"R88-20250604","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series.","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"R89-20250604","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/TXD.0000000000000971","article-title":"The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients.","volume":"6","author":"Kukla","year":"2020","journal-title":"Transplant Direct"},{"key":"R90-20250604","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"R91-20250604","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight.","volume":"15","author":"Shah","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"R92-20250604","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s13300-020-00786-1","article-title":"A Retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation.","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther"},{"key":"R93-20250604","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ckj\/sfx117","article-title":"A comparative analysis of survival of patients on dialysis and after kidney transplantation.","volume":"11","author":"Kaballo","year":"2018","journal-title":"Clin Kidney J"},{"issue":"suppl s1","key":"R94-20250604","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ajt.15672","article-title":"OPTN\/SRTR 2018 annual data report: kidney.","volume":"20","author":"Hart","year":"2020","journal-title":"Am J Transplant"},{"issue":"suppl 12","key":"R95-20250604","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1681\/ASN.2006080930","article-title":"Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation.","volume":"17","author":"Morales","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R96-20250604","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/sj.bjp.0705659","article-title":"Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats.","volume":"141","author":"Gardiner","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R97-20250604","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1172\/JCI117222","article-title":"Vascular mechanisms of cyclosporin-induced hypertension in the rat.","volume":"93","author":"Roullet","year":"1994","journal-title":"J Clin Invest"},{"key":"R98-20250604","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.","volume":"17","author":"Hoorn","year":"2011","journal-title":"Nat Med"},{"key":"R99-20250604","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00007890-199207000-00009","article-title":"Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation.","volume":"54","author":"Perico","year":"1992","journal-title":"Transplantation"},{"key":"R100-20250604","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/HJH.0b013e32835165e4","article-title":"Hypertension after kidney transplantation: calcineurin inhibitors increase salt-sensitivity.","volume":"30","author":"Hoorn","year":"2012","journal-title":"J Hypertens"},{"issue":"Pt 2","key":"R101-20250604","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/bj2750501","article-title":"Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis.","volume":"275","author":"Princen","year":"1991","journal-title":"Biochem J"},{"key":"R102-20250604","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/ndt\/gfn004","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.","volume":"23","author":"Kr\u00e4mer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R103-20250604","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(02)07875-3","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study.","volume":"359","author":"Margreiter","year":"2002","journal-title":"Lancet"},{"key":"R104-20250604","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"R105-20250604","doi-asserted-by":"crossref","first-page":"E365","DOI":"10.1152\/ajpendo.00390.2004","article-title":"Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity.","volume":"288","author":"Radu","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R107-20250604","doi-asserted-by":"crossref","first-page":"2324709617706087","DOI":"10.1177\/2324709617706087","article-title":"Tacrolimus-associated dilated cardiomyopathy in adult patient after orthotopic liver transplant.","volume":"5","author":"McLeod","year":"2017","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R108-20250604","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/rheumatology\/kex310","article-title":"Tacrolimus-induced hypertrophic cardiomyopathy in a patient with dermatomyositis.","volume":"56","author":"Noda","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R109-20250604","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.ijcard.2014.07.171","article-title":"Tacrolimus-induced left ventricular apical hypertrophy in a patient with post-allogeneic hematopoietic stem cell transplantation.","volume":"177","author":"Takeuchi","year":"2014","journal-title":"Int J Cardiol"},{"key":"R110-20250604","first-page":"116","article-title":"Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients.","volume":"13","author":"Dehghani","year":"2010","journal-title":"Arch Iran Med"},{"key":"R111-20250604","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_6_17","article-title":"Tacrolimus as a rare cause of pericardial effusion in a renal transplant recipient.","volume":"18","author":"Prashar","year":"2017","journal-title":"Heart Views"},{"key":"R112-20250604","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1097\/MJT.0000000000000630","article-title":"Cardiac tamponade induced by tacrolimus toxicity.","volume":"25","author":"Doobay","year":"2018","journal-title":"Am J Ther"},{"key":"R113-20250604","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R114-20250604","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R115-20250604","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation.","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"R116-20250604","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R117-20250604","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation.","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R118-20250604","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation"},{"key":"R119-20250604","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1097\/TP.0000000000001589","article-title":"Belatacept compared with tacrolimus for kidney transplantation: a propensity score matched cohort study.","volume":"101","author":"Cohen","year":"2017","journal-title":"Transplantation"},{"key":"R120-20250604","doi-asserted-by":"crossref","first-page":"e13903","DOI":"10.1111\/ctr.13903","article-title":"Alternatives to immediate release tacrolimus in solid organ transplant recipients: when the gold standard is in short supply.","volume":"34","author":"Jorgenson","year":"2020","journal-title":"Clin Transplant"},{"key":"R121-20250604","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5152\/tud.2013.004","article-title":"Comparison of tacrolimus with a cyclosporine microemulsion for immunosuppressive therapy in kidney transplantation.","volume":"39","author":"Ekmek\u00e7io\u011flu","year":"2013","journal-title":"Turk J Urol"},{"key":"R122-20250604","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.ekir.2018.07.009","article-title":"Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus.","volume":"3","author":"Torres","year":"2018","journal-title":"Kidney Int Rep"},{"key":"R123-20250604","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1399-0012.1997.tb00782.x","article-title":"Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation.","volume":"11","author":"Guckelberger","year":"1997","journal-title":"Clin Transplant"},{"key":"R124-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/lt.500030101","article-title":"Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506).","volume":"3","author":"Canzanello","year":"1997","journal-title":"Liver Transpl Surg"},{"key":"R125-20250604","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents.","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Transplant"},{"key":"R126-20250604","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2019.01.031","article-title":"Management of kidney transplant recipients by general nephrologists: core curriculum 2019.","volume":"73","author":"Voora","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R127-20250604","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"key":"R128-20250604","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R129-20250604","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1399-0012.2006.00613.x","article-title":"Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.","volume":"21","author":"Jaber","year":"2007","journal-title":"Clin Transplant"},{"key":"R130-20250604","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/j.1600-6143.2006.01477.x","article-title":"Short-term experience with early steroid withdrawal in African-American renal transplant recipients.","volume":"6","author":"Haririan","year":"2006","journal-title":"Am J Transplant"},{"key":"R131-20250604","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.ackd.2016.09.007","article-title":"Immunosuppression minimization and avoidance protocols: when less is not more.","volume":"23","author":"Prashar","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"R132-20250604","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1016\/j.transproceed.2010.09.084","article-title":"Low-dose steroid maintenance for renal transplant recipients.","volume":"42","author":"Kishikawa","year":"2010","journal-title":"Transplant Proc"},{"key":"R133-20250604","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-6143.2004.00765.x","article-title":"Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients.","volume":"5","author":"Opelz","year":"2005","journal-title":"Am J Transplant"},{"key":"R134-20250604","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"R135-20250604","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamasurg.2020.6929","article-title":"Early corticosteroid cessation vs long-term corticosteroid therapy in kidney transplant recipients: long-term outcomes of a randomized clinical trial.","volume":"156","author":"Woodle","year":"2021","journal-title":"JAMA Surg"},{"key":"R136-20250604","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/TP.0b013e3181e58912","article-title":"A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation.","volume":"90","author":"Pascual","year":"2010","journal-title":"Transplantation"},{"key":"R137-20250604","first-page":"CD005632","article-title":"Steroid avoidance or withdrawal for kidney transplant recipients.","author":"Pascual","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R138-20250604","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1097\/TP.0000000000001756","article-title":"Rapid discontinuation of prednisone in kidney transplant recipients: 15-year outcomes from the University of Minnesota.","volume":"101","author":"Serrano","year":"2017","journal-title":"Transplantation"},{"key":"R139-20250604","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.47.6.1297","article-title":"Variations in arterial blood pressure after kidney transplantation. Relation to renal function, plasma renin activity, and the dose of prednisone.","volume":"47","author":"Popovtzer","year":"1973","journal-title":"Circulation"},{"key":"R140-20250604","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ki.1987.131","article-title":"Mechanisms of glucocorticoid-induced hypertension.","volume":"31","author":"Whitworth","year":"1987","journal-title":"Kidney Int"},{"issue":"suppl 7","key":"R141-20250604","doi-asserted-by":"crossref","first-page":"381s","DOI":"10.1042\/cs061381s","article-title":"Does long-term low-dose corticosteroid therapy cause hypertension?","volume":"61","author":"Jackson","year":"1981","journal-title":"Clin Sci (Lond)"},{"key":"R142-20250604","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/j.1600-6143.2005.01051.x","article-title":"Prednisone-free maintenance immunosuppression\u2014a 5-year experience.","volume":"5","author":"Matas","year":"2005","journal-title":"Am J Transplant"},{"key":"R143-20250604","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1399-0012.2004.00298.x","article-title":"Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies.","volume":"19","author":"Kumar","year":"2005","journal-title":"Clin Transplant"},{"issue":"suppl 1","key":"R144-20250604","first-page":"5","article-title":"Practical considerations for the use of mTOR inhibitors.","volume":"4","author":"Diekmann","year":"2015","journal-title":"Transplant Res"},{"key":"R145-20250604","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"R146-20250604","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different.","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R147-20250604","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"R148-20250604","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors.","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"R149-20250604","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.2013060663","article-title":"Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients.","volume":"25","author":"Ducloux","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R150-20250604","doi-asserted-by":"crossref","first-page":"861370","DOI":"10.1155\/2009\/861370","article-title":"Non-ST elevation myocardial infraction after high dose intravenous immunoglobulin infusion.","volume":"2009","author":"Mizrahi","year":"2009","journal-title":"Case Rep Med"},{"key":"R151-20250604","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard.59.1.77","article-title":"Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases.","volume":"59","author":"Elkayam","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R152-20250604","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00043426-199705000-00015","article-title":"Cardiac rhythm abnormalities during intravenous immunoglobulin G infusion for treatment of thrombocytopenia.","volume":"19","author":"Sava\u015fan","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"R153-20250604","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ccr3.329","article-title":"Cardiac rhythm abnormalities during intravenous immunoglobulin G (IVIG) infusion in two newborn infants: coincidence or association?","volume":"3","author":"Tufekci","year":"2015","journal-title":"Clin Case Rep"},{"key":"R154-20250604","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0140-6736(92)90806-E","article-title":"Effect of high-dose intravenous immunoglobulin therapy on blood rheology.","volume":"339","author":"Reinhart","year":"1992","journal-title":"Lancet"},{"key":"R155-20250604","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-004-0895-2","article-title":"Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.","volume":"83","author":"Hefer","year":"2004","journal-title":"Ann Hematol"},{"key":"R156-20250604","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"R157-20250604","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.01701105","article-title":"Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.","volume":"1","author":"Vo","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R158-20250604","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.ajkd.2017.11.018","article-title":"Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis.","volume":"72","author":"Tang","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R159-20250604","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/nep.12595","article-title":"Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients.","volume":"21","author":"Reque","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"R160-20250604","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11255-007-9269-8","article-title":"The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients.","volume":"40","author":"Acarturk","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"R161-20250604","doi-asserted-by":"crossref","first-page":"e003940","DOI":"10.1161\/CIRCHEARTFAILURE.116.003940","article-title":"Pulmonary hypertension is associated with a higher risk of heart failure hospitalization and mortality in patients with chronic kidney disease: the Jackson Heart Study.","volume":"10","author":"Selvaraj","year":"2017","journal-title":"Circ Heart Fail"},{"key":"R162-20250604","first-page":"606","article-title":"Pulmonary hypertension in end-stage renal disease and post renal transplantation patients.","volume":"6","author":"Alhamad","year":"2014","journal-title":"J Thorac Dis"},{"key":"R163-20250604","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4103\/1319-2442.118080","article-title":"Progressive pulmonary hypertension: another criterion for expeditious renal transplantation.","volume":"24","author":"Reddy","year":"2013","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R164-20250604","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1016\/j.transproceed.2010.06.026","article-title":"The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension.","volume":"42","author":"Casas-Aparicio","year":"2010","journal-title":"Transplant Proc"},{"key":"R165-20250604","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1378\/chest.123.5.1577","article-title":"Pulmonary hypertension in patients with end-stage renal disease.","volume":"123","author":"Yigla","year":"2003","journal-title":"Chest"},{"key":"R166-20250604","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/TP.0b013e318188d640","article-title":"Pulmonary hypertension is associated with reduced patient survival after kidney transplantation.","volume":"86","author":"Issa","year":"2008","journal-title":"Transplantation"},{"key":"R167-20250604","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1093\/ndt\/gfq141","article-title":"Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction.","volume":"25","author":"Zlotnick","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R168-20250604","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/TP.0b013e31828dbbbe","article-title":"Do echocardiographic parameters predict mortality in patients with end-stage renal disease?","volume":"95","author":"Stallworthy","year":"2013","journal-title":"Transplantation"},{"key":"R169-20250604","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.amjcard.2017.05.006","article-title":"Renal allograft outcome after simultaneous heart and kidney transplantation.","volume":"120","author":"Grupper","year":"2017","journal-title":"Am J Cardiol"},{"issue":"suppl 1","key":"R170-20250604","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2215\/CJN.04860709","article-title":"Left ventricular mass in chronic kidney disease and ESRD.","volume":"4","author":"Glassock","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R171-20250604","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.1989.192","article-title":"Impact of left ventricular hypertrophy on survival in end-stage renal disease.","volume":"36","author":"Silberberg","year":"1989","journal-title":"Kidney Int"},{"key":"R172-20250604","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1681\/ASN.2005040439","article-title":"Comorbid conditions in kidney transplantation: association with graft and patient survival.","volume":"16","author":"Wu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R173-20250604","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/TP.0b013e3182a688e5","article-title":"Predictors of graft failure and death in elderly kidney transplant recipients.","volume":"96","author":"Faravardeh","year":"2013","journal-title":"Transplantation"},{"key":"R174-20250604","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1097\/01.tp.0000295748.42884.97","article-title":"The impact of left ventricular systolic dysfunction on survival after renal transplantation.","volume":"84","author":"Siedlecki","year":"2007","journal-title":"Transplantation"},{"key":"R175-20250604","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e31817ef0f9","article-title":"Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review.","volume":"86","author":"Lentine","year":"2008","journal-title":"Transplantation"},{"key":"R176-20250604","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"R177-20250604","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the national heart, lung, and blood institute.","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"R178-20250604","doi-asserted-by":"crossref","first-page":"71154","DOI":"10.18632\/oncotarget.16862","article-title":"The prognostic significance of preoperative left ventricular diastolic dysfunction and left atrial enlargement on acute coronary syndrome in kidney transplantation.","volume":"8","author":"Hwang","year":"2017","journal-title":"Oncotarget"},{"key":"R179-20250604","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3349\/ymj.2019.60.3.291","article-title":"The impact of perioperative factors on changes in diastolic function after kidney transplantation: a retrospective analysis.","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J"},{"key":"R180-20250604","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2337\/diacare.23.12.1804","article-title":"Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients.","volume":"23","author":"Fiorina","year":"2000","journal-title":"Diabetes Care"},{"key":"R181-20250604","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7150\/ijms.15745","article-title":"Predictive value of echocardiographic abnormalities and the impact of diastolic dysfunction on in-hospital major cardiovascular complications after living donor kidney transplantation.","volume":"13","author":"Kim","year":"2016","journal-title":"Int J Med Sci"},{"key":"R182-20250604","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/CIRCULATIONAHA.116.022249","article-title":"Heart failure with preserved ejection fraction: a kidney disorder?","volume":"134","author":"Fang","year":"2016","journal-title":"Circulation"},{"key":"R183-20250604","doi-asserted-by":"crossref","first-page":"e013389","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects.","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R184-20250604","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials.","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"R185-20250604","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R186-20250604","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"R187-20250604","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R188-20250604","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2004.11.061","article-title":"Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease.","volume":"45","author":"Wali","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R189-20250604","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/ehf2.13283","article-title":"Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis.","volume":"8","author":"Pickup","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R190-20250604","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R191-20250604","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease.","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"R193-20250604","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000064476","article-title":"Hospitalizations for valvular heart disease in chronic dialysis patients in the United States.","volume":"92","author":"Abbott","year":"2002","journal-title":"Nephron"},{"key":"R194-20250604","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/ndt\/gfz053","article-title":"Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies.","volume":"34","author":"Rangaswami","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R195-20250604","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5414\/CNP59079","article-title":"Hospitalized valvular heart disease in patients on renal transplant waiting list: incidence, clinical correlates and outcomes.","volume":"59","author":"Abbott","year":"2003","journal-title":"Clin Nephrol"},{"key":"R196-20250604","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1161\/CIRCULATIONAHA.109.912170","article-title":"Survival of kidney transplantation patients in the United States after cardiac valve replacement.","volume":"121","author":"Sharma","year":"2010","journal-title":"Circulation"},{"key":"R197-20250604","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jjcc.2013.01.016","article-title":"Transcatheter aortic valve implantation improves outcome compared to open-heart surgery in kidney transplant recipients requiring aortic valve replacement.","volume":"61","author":"Fox","year":"2013","journal-title":"J Cardiol"},{"key":"R198-20250604","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2018.05.005","article-title":"Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"94","author":"Wanner","year":"2018","journal-title":"Kidney Int"},{"key":"R199-20250604","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1017976230742","article-title":"Arrhythmias and risk assessment in patients with renal failure.","volume":"6","author":"Girgis","year":"2002","journal-title":"Card Electrophysiol Rev"},{"key":"R200-20250604","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2215\/CJN.00920805","article-title":"Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation.","volume":"1","author":"Lentine","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R201-20250604","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/TP.0b013e3182a2b492","article-title":"Incidence and predictors of postoperative atrial fibrillation in kidney transplant recipients.","volume":"96","author":"La Manna","year":"2013","journal-title":"Transplantation"},{"key":"R202-20250604","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1034\/j.1600-6143.2003.00071.x","article-title":"Hospitalized atrial fibrillation after renal transplantation in the United States.","volume":"3","author":"Abbott","year":"2003","journal-title":"Am J Transplant"},{"key":"R203-20250604","doi-asserted-by":"crossref","first-page":"e007954","DOI":"10.1161\/CIRCEP.120.007954","article-title":"Management of arrhythmias after heart transplant: current state and considerations for future research.","volume":"14","author":"Joglar","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R204-20250604","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/ndt\/gfm766","article-title":"Pre-transplant predictors of cerebrovascular events after kidney transplantation.","volume":"23","author":"Aull-Watschinger","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R205-20250604","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/ctr.12765","article-title":"Risk factors and outcome of stroke in renal transplant recipients.","volume":"30","author":"Findlay","year":"2016","journal-title":"Clin Transplant"},{"key":"R206-20250604","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/ndt\/gfx265","article-title":"Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?","volume":"33","author":"Malyszko","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"R207-20250604","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/tri.13599","article-title":"Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study.","volume":"33","author":"Bixby","year":"2020","journal-title":"Transpl Int"},{"key":"R208-20250604","doi-asserted-by":"crossref","first-page":"e13853","DOI":"10.1111\/ctr.13853","article-title":"Utilization of direct-acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices.","volume":"34","author":"Lichvar","year":"2020","journal-title":"Clin Transplant"},{"key":"R209-20250604","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2016.04.170","article-title":"Sudden cardiac death and chronic kidney disease: from pathophysiology to treatment strategies.","volume":"217","author":"Di Lullo","year":"2016","journal-title":"Int J Cardiol"},{"key":"R210-20250604","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199610150-00025","article-title":"Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death.","volume":"62","author":"West","year":"1996","journal-title":"Transplantation"},{"key":"R211-20250604","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1432-2277.2010.01149.x","article-title":"Ventricular arrhythmia in incident kidney transplant recipients: prevalence and associated factors.","volume":"24","author":"Marcassi","year":"2011","journal-title":"Transpl Int"},{"key":"R212-20250604","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.nefro.2015.03.001","article-title":"Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease.","volume":"35","author":"Alkhouli","year":"2015","journal-title":"Nefrologia"},{"key":"R213-20250604","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1086\/681266","article-title":"Case series of 5 patients with end-stage renal disease with reversible dyspnea, heart failure, and pulmonary hypertension related to arteriovenous dialysis access.","volume":"5","author":"Raza","year":"2015","journal-title":"Pulm Circ"},{"key":"R214-20250604","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1432-2277.2010.01159.x","article-title":"Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk.","volume":"23","author":"Liefeldt","year":"2010","journal-title":"Transpl Int"},{"key":"R215-20250604","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.1993.289","article-title":"Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup.","volume":"44","author":"Manske","year":"1993","journal-title":"Kidney Int"},{"key":"R216-20250604","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/TP.0000000000000611","article-title":"Prognostic value of cardiac tests in potential kidney transplant recipients: a systematic review.","volume":"99","author":"Wang","year":"2015","journal-title":"Transplantation"},{"key":"R217-20250604","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2215\/CJN.05351107","article-title":"Cardiac evaluation before kidney transplantation: a practice patterns analysis in medicare-insured dialysis patients.","volume":"3","author":"Lentine","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R218-20250604","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.jacc.2012.07.012","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"}],"updated-by":[{"DOI":"10.1097\/tp.0000000000004320","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:10:02Z","timestamp":1749064202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":214,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003990","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}